Key facts
- It has raised $145.0M across 1 recorded rounds; the latest was Early Stage VC (Series B) ($145.0M) in May 2020.
- 2 institutional filers report fund marks on Rallybio across 4 filings.
- Rallybio has filed 1 Form D with the SEC, most recently Apr 2024 ($6.6M sold to 1 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Rallybio
Create free account
No card required
Funding rounds
1 roundsMay 2020Early Stage VC (Series B)$145.0M▮
About Rallybio
- Industry
- Drug Discovery
PA Mark — not yet priced
Rallybio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Rallybio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
2 filers · latest Jun 20262 SEC-registered funds reported 4 fair-value marks on Rallybio between Mar 2026 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.